drugset / Trial / NCT04157127
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Timeline
- Start
- 2020-08-03
- Primary completion
- 2026-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous DC Therapy | Unknown | 2 cells | Other |
| Subject | Autologous DC Therapy | Unknown | 8 cells | Other |
| Subject | Autologous DC Therapy | Unknown | 12 cells | Other |